Interferon Gamma
- Generic Name
- Interferon Gamma
- Drug Type
- Biotech
- Unique Ingredient Identifier
- P050J5FWC5
- Background
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
- Associated Conditions
- Serious infections
The 1st Tumor CytokinoTherapy Database (TCTD-1)
- Conditions
- Oncology
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- OncoCareClinic 308 Ltd
- Target Recruit Count
- 5000
- Registration Number
- NCT06222801
- Locations
- 🇷🇺
OncocareClinic 308, Moscow, Russian Federation
A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06118619
- Locations
- 🇷🇺
Tuberculosis Clinic of the Chuvash Republic, Cheboksary, Chuvash Republic, Russian Federation
🇷🇺Clinical Phthisiopulmonological Medical Center, Perm, Perm Region, Russian Federation
🇷🇺Leningrad Oblast Tuberculosis Clinic, Slantsy, Leningrad Oblast, Russian Federation
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients
- Conditions
- Pneumonia, Ventilator-Associated
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 132
- Registration Number
- NCT05843786
- Locations
- 🇫🇷
CHU Limoges, Limoges, France
🇫🇷Service de reanimation chirurgicale Hopital Croix-Rousse, Lyon, France
🇫🇷Hôpital Edouard Herriot - Médecine intensive - réanimation, Lyon, France
Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 114
- Registration Number
- NCT05395702
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation
Study of the Use of the Drug Ingaron in Patients With COVID-19
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05386459
- Locations
- 🇷🇺
City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation
Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05359315
- Locations
- 🇷🇺
FSBI "NMIC FPI" of the Ministry of Health of Russia, Moscow, Russian Federation
Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
- Conditions
- Aids/Hiv ProblemHuman Immunodeficiency VirusLentivirus InfectionsHIV CoinfectionTuberculosis, PulmonaryRNA Virus Infections
- Interventions
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- SPP Pharmaclon Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05065905
- Locations
- 🇷🇺
Saint-Petersburg State Medical Academy n.a. I.I.Mechnikov of Ministry of Health, Saint Petersburg, Saint-Petersburg, Russian Federation
🇷🇺City Tuberculosis Hospital #2 of Saint-Petersburg, Saint Petersburg, Saint-Petersburg, Russian Federation
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
- Conditions
- Glioblastoma or Gliosarcoma
- Interventions
- Drug: Single intratumoral injection of DNX-2401
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- DNAtrix, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02197169
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Baylor University: Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Cancer
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT00501644
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis
- Conditions
- Reactive Arthritis
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2006-09-08
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT00244179
- Locations
- 🇩🇪
Charite Campus Benjamin Franklin, Rheumatology, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.